Jan 28 (Reuters) - Novo Nordisk said on
Tuesday the U.S. FDA has approved its diabetes drug Ozempic to
reduce the risk of worsening kidney disease and death due to
cardiovascular disease in adults with type 2 diabetes and
chronic kidney disease.